STOCK TITAN
  1. Home
  2. Sec-filings
  3. LLY
  4. [Form 4] ELI LILLY & Co Insider Trading Activity

LLY insider sales across $1,001.213–$1,021.661 price ranges

Filing Impact
(Very High)
Filing Sentiment
(Very Negative)
Form Type
4

Rhea-AI Filing Summary

Eli Lilly (LLY) reported insider activity on a Form 4 showing multiple open‑market sales of common stock on 11/12/2025. The transactions were executed in several tranches at weighted‑average prices disclosed in footnotes.

Following the reported sales, the reporting person beneficially owned 93,106,978 shares, held directly. Footnotes note the sales occurred across price ranges from $1,001.213 to $1,021.661, with the reporting person able to provide detailed trade breakdowns upon request.

Positive

  • None.

Negative

  • None.
Insider LILLY ENDOWMENT INC
Role 10% Owner
Sold 305,000 shs ($308.41M)
Type Security Shares Price Value
Sale Common Stock 828 $1,001.93 $830K
Sale Common Stock 7,585 $1,003.116 $7.61M
Sale Common Stock 22,131 $1,004.099 $22.22M
Sale Common Stock 23,568 $1,004.968 $23.69M
Sale Common Stock 23,863 $1,006.017 $24.01M
Sale Common Stock 16,383 $1,007.099 $16.50M
Sale Common Stock 8,913 $1,007.968 $8.98M
Sale Common Stock 17,985 $1,009.00 $18.15M
Sale Common Stock 20,000 $1,009.987 $20.20M
Sale Common Stock 19,892 $1,011.177 $20.11M
Sale Common Stock 21,559 $1,011.961 $21.82M
Sale Common Stock 16,749 $1,012.942 $16.97M
Sale Common Stock 11,638 $1,014.169 $11.80M
Sale Common Stock 16,274 $1,015.158 $16.52M
Sale Common Stock 13,415 $1,016.005 $13.63M
Sale Common Stock 7,188 $1,017.156 $7.31M
Sale Common Stock 47,073 $1,018.022 $47.92M
Sale Common Stock 7,833 $1,018.829 $7.98M
Sale Common Stock 1,281 $1,019.919 $1.31M
Sale Common Stock 842 $1,021.065 $860K
Holdings After Transaction: Common Stock — 93,411,150 shares (Direct)
Footnotes (1)
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,001.213 to $1,002.20, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), (16), (17), (18), (19), and (20) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,002.52 to $1,003.51, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,003.52 to $1,004.515, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,004.53 to $1,005.527, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,005.535 to $1,006.53, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,006.54 to $1,007.53, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,007.54 to $1,008.52, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,008.54 to $1,009.535, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,009.54 to $1,010.53, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,010.54 to $1,011.53, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,011.55 to $1,012.545, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,012.55 to $1,013.532, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,013.59 to $1,014.56, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,014.59 to $1,015.58, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,015.59 to $1,016.439, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,016.60 to $1,017.54, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,017.63 to $1,018.62, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,018.65 to $1,019.421, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,019.651 to $1,020.375 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,020.664 to $1,021.661, inclusive.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
LILLY ENDOWMENT INC
(Last) (First) (Middle)
2801 NORTH MERIDIAN STREET
(Street)
INDIANAPOLIS IN 46208-0068
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ELI LILLY & Co [ LLY ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
11/12/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/12/2025 S 828 D $1,001.93(1) 93,411,150 D
Common Stock 11/12/2025 S 7,585 D $1,003.116(2) 93,403,565 D
Common Stock 11/12/2025 S 22,131 D $1,004.099(3) 93,381,434 D
Common Stock 11/12/2025 S 23,568 D $1,004.968(4) 93,357,866 D
Common Stock 11/12/2025 S 23,863 D $1,006.017(5) 93,334,003 D
Common Stock 11/12/2025 S 16,383 D $1,007.099(6) 93,317,620 D
Common Stock 11/12/2025 S 8,913 D $1,007.968(7) 93,308,707 D
Common Stock 11/12/2025 S 17,985 D $1,009(8) 93,290,722 D
Common Stock 11/12/2025 S 20,000 D $1,009.987(9) 93,270,722 D
Common Stock 11/12/2025 S 19,892 D $1,011.177(10) 93,250,830 D
Common Stock 11/12/2025 S 21,559 D $1,011.961(11) 93,229,271 D
Common Stock 11/12/2025 S 16,749 D $1,012.942(12) 93,212,522 D
Common Stock 11/12/2025 S 11,638 D $1,014.169(13) 93,200,884 D
Common Stock 11/12/2025 S 16,274 D $1,015.158(14) 93,184,610 D
Common Stock 11/12/2025 S 13,415 D $1,016.005(15) 93,171,195 D
Common Stock 11/12/2025 S 7,188 D $1,017.156(16) 93,164,007 D
Common Stock 11/12/2025 S 47,073 D $1,018.022(17) 93,116,934 D
Common Stock 11/12/2025 S 7,833 D $1,018.829(18) 93,109,101 D
Common Stock 11/12/2025 S 1,281 D $1,019.919(19) 93,107,820 D
Common Stock 11/12/2025 S 842 D $1,021.065(20) 93,106,978 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,001.213 to $1,002.20, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), (16), (17), (18), (19), and (20) to this Form 4.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,002.52 to $1,003.51, inclusive.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,003.52 to $1,004.515, inclusive.
4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,004.53 to $1,005.527, inclusive.
5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,005.535 to $1,006.53, inclusive.
6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,006.54 to $1,007.53, inclusive.
7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,007.54 to $1,008.52, inclusive.
8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,008.54 to $1,009.535, inclusive.
9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,009.54 to $1,010.53, inclusive.
10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,010.54 to $1,011.53, inclusive.
11. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,011.55 to $1,012.545, inclusive.
12. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,012.55 to $1,013.532, inclusive.
13. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,013.59 to $1,014.56, inclusive.
14. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,014.59 to $1,015.58, inclusive.
15. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,015.59 to $1,016.439, inclusive.
16. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,016.60 to $1,017.54, inclusive.
17. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,017.63 to $1,018.62, inclusive.
18. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,018.65 to $1,019.421, inclusive.
19. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,019.651 to $1,020.375 inclusive.
20. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,020.664 to $1,021.661, inclusive.
/s/ Peter A. Buck, Vice President for Investments & Grants Administration, on behalf of Lilly Endowment Inc. 11/13/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Eli Lilly (LLY) disclose in this Form 4?

Multiple open‑market sales of common stock on 11/12/2025 at weighted‑average prices, reported across several tranches.

How many Eli Lilly shares are beneficially owned after the transactions?

The reporting person beneficially owned 93,106,978 shares following the reported sales, held directly.

What price ranges were involved in the sales on 11/12/2025?

Footnotes disclose weighted‑average price ranges from $1,001.213 to $1,021.661 across the reported tranches.

Were the sales executed in a single trade or multiple trades?

They were executed in multiple transactions, with each tranche reported at a weighted‑average price.

Does the Form 4 specify the reporting person’s ownership form?

Yes. Ownership is listed as Direct (D) after the transactions.

Can investors obtain the exact trade quantities and prices?

Yes. The reporting person undertakes to provide full information for each price within the stated ranges upon request.